CNBC caught up with Biogen CEO George Scangos to discuss where he leaves the big biotech after six years at the helm. » Read More
Stocks staged a relief rally Wednesday amid talks of a bailout for Greece and positive earnings and sales news from some key Dow components.
U.S. stock index futures are pointing to a higher open Tuesday morning, a day after a last-hour selloff pushed the Dow to its first close below 10,000 since November, and the S&P 500 to a fresh three-month closing low as well.
What follows is a roundup of corporate earnings reports for Tuesday, Feb. 9.
Thirteen-grand a year. That's about how much Acorda Therapeutics says it'll charge for its newly approved drug Ampyra for multiple sclerosis.
Pfizer, the world's largest drugmaker, is scheduled to report fourth-quarter results before the opening bell on Wednesday, February 3. Here is a look at how Pfizer shares traded during the most recent earnings reports.
The Chairman and CEO of Alkermes had the chutzpah to get on Twitter yesterday. And he apparently isn’t just there to be a voyeur and to keep an eye on what’s being said in the biopharma Twitterverse. Pops has already sent out at least a couple of tweets.
I'm gonna avoid all the cliches about JPM being the Super Bowl of investment conferences or the grandaddy of them all. As of earlier this week, JPM says 6,500 people are expected to attend (down slightly from last year,) more than 330 public and private companies are presenting and more than 7,500 so-called one-on-one meetings between analysts/investors and execs have been scheduled. Plus, a whole bunch of other meetings take place on the down low all over the city.
Talk about a blow to the ego. The shares may have since succumbed to the downdraft in the overall stock market, but when trading opened this morning Biogen Idec shot up around two percent. Investors were reacting to the news that the company's longtime CEO, Jim Mullen, is calling it quits.
It has been over a month and a half since the US House of Representatives passed its version of health care reform and today, the Senate passed its bill. Now the two bills must be reconciled and the debate will continue to heat up. Here are the biggest S&P Health Care gainers and losers over the past 6 months.
Our whales aren’t massive sea creatures, so much as massive investors who are massively wealthy... and they’ve recently surfaced to reveal their top holdings.
This weekend, the US House of Representatives passed its version of health care reform and now awaits a version from the Senate. The debate has been heating up since earlier this summer when President Obama was pushing for legislation before the summer recess. Here are the biggest S&P Health Care gainers and losers over while the debate has waged on.
Stocks retreated Tuesday after several earnings reports beat expectations but economic numbers missed their targets. The Dow shed more than 50 points, or 0.5 percent, but still held above 10,000. The S&P and Nasdaq each lost about 0.6 percent.
Stocks retreated Tuesday after several earnings reports beat expectations but economic numbers missed their targets. Apple and Caterpillar surged after their earnings blew past forecasts.
Futures were poised for a modestly higher open on the strength of more earnings surprises from some of Wall Street's leading companies.
Following are the day’s biggest winners and losers. Find out why shares of Nike and Huntington Bancshares popped while Biogen and Saks dropped.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
With new data showing that consumers are unlikely to help spark growth anytime soon, can the market sustain its recent gains?
Biotech companies continued their rally today, with the biotech index up more than 35 percent in the last three months. Eric Schmidt, biotech analyst at Cowen, and Joel Sendek, managing director and biotech analyst at Lazard Capital Markets, explained the force behind the comeback and the best stock plays for investors right now.
Stocks continued to struggle on Friday. Could this be the beginning of a real market correction? Mike Rubino, president of Rubino Financial, and Paul Schatz, president of Heritage Capital, discussed how investors should position their portfolios for the end of the third quarter.
Big money managers can instill confidence in individual stocks and you may be able to profit off their moves. Karen Finerman breaks down the holdings of the major money managers.